Translational Regenerative Medicines - Global ﾂ鮓ｹﾔｭｴｴ Outlook (2017-2026)

Publication ID:

SMRC0519052

Publication Date:

May 1, 2019

Pages:

158

Publisher:

Stratistics MRC

Countries:

Global [1]

USD 4,150.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ is growing at a CAGR of 13.9% from 2017 to 2026. Factors such as the increasing prevalence of degenerative diseases, rise in aging population and growing advancements in developed countries are the major driving factors. However, ethical concerns related to the use of embryonic stem cells in research & development hinders market growth.

Regenerative medicine is a segment of translational research in molecular biology and tissue engineering. It involves the process of regeneration of human cells, tissues, or organs to re-establish their normal functions through stimulation of the body窶冱 repair system. They are widely used in the treatment of many degenerative disorders occurring in the areas of dermatology, orthopedic, cardiovascular and neurodegenerative diseases.

By Product Type, the Gene therapy segment is expected to have significant growth during the forecast period. Gene therapy assists the foundation for innovative treatments of innumerable musculoskeletal disorders. By geography, North America dominated the global regenerative medicine market owing to an increased number of leading companies and growth in the expansion of research and development activities in the U.S.

Some of the key players profiled in the Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ include Vericel Corporation, Gamida Cell Ltd., Athersys, Inc., Orthofix International N.V, Anika Therapeutics, Novartis, Celgene Corporation, Brainstorm Cell Therapeutics Inc., Nuvasive, Inc., and Medipost.

Product Types Covered:
窶｢ Cell-Based Products
窶｢ Tissue Engineered Products
窶｢ Gene Therapy Products

Applications Covered:
窶｢ Dermatology
窶｢ Cardiovascular
窶｢ Oncology
窶｢ Diabetes
窶｢ Orthopedic
窶｢ Neurology
窶｢ Other Applications

Regions Covered:
窶｢ North America
o US
o Canada
o Mexico
窶｢ Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
窶｢ Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
窶｢ South America
o Argentina
o Brazil
o Chile
o Rest of South America
窶｢ Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- ﾂ鮓ｹﾔｭｴｴ share assessments for the regional and country level segments
- ﾂ鮓ｹﾔｭｴｴ share analysis of the top industry players
- Strategic recommendations for the new entrants
- ﾂ鮓ｹﾔｭｴｴ forecasts for a minimum of 9 years of all the mentioned segments, , and the regional markets
- ﾂ鮓ｹﾔｭｴｴ Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
窶｢ Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
窶｢ Regional Segmentation
o ﾂ鮓ｹﾔｭｴｴ estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
窶｢ Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table Of Contents:

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 ﾂ鮓ｹﾔｭｴｴ Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 Emerging ﾂ鮓ｹﾔｭｴｴs
3.9 Futuristic ﾂ鮓ｹﾔｭｴｴ Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ, By Product Type
5.1 Introduction
5.2 Cellular
5.3 Acellular

6 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ, By Therapy
6.1 Introduction
6.2 Gene Therapy
6.3 Cell Therapy
6.4 Immunotherapy
6.5 Tissue Engineering

7 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ, By Application
7.1 Introduction
7.2 Dermatology
7.3 Cardiovascular
7.4 Oncology
7.5 Diabetes
7.6 Orthopedic
7.7 Neurology
7.8 Other Applications

8 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa

9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling
10.1 Vericel Corporation
10.2 Gamida Cell Ltd.
10.3 Athersys, Inc.
10.4 Orthofix International N.V
10.5 Anika Therapeutics
10.6 Novartis
10.7 Celgene Corporation
10.8 Brainstorm Cell Therapeutics Inc.
10.9 Nuvasive, Inc.
10.10 Medipost

List of Tables
Table 1 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 3 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cellular (2016-2026) (US $MN)
Table 4 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Acellular (2016-2026) (US $MN)
Table 5 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Therapy (2016-2026) (US $MN)
Table 6 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Gene Therapy (2016-2026) (US $MN)
Table 7 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cell Therapy (2016-2026) (US $MN)
Table 8 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunotherapy (2016-2026) (US $MN)
Table 9 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Tissue Engineering (2016-2026) (US $MN)
Table 10 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Application (2016-2026) (US $MN)
Table 11 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Dermatology (2016-2026) (US $MN)
Table 12 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 13 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Oncology (2016-2026) (US $MN)
Table 14 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Diabetes (2016-2026) (US $MN)
Table 15 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Orthopedic (2016-2026) (US $MN)
Table 16 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Neurology (2016-2026) (US $MN)
Table 17 Global Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Applications (2016-2026) (US $MN)
Table 18 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 19 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 20 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cellular (2016-2026) (US $MN)
Table 21 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Acellular (2016-2026) (US $MN)
Table 22 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Therapy (2016-2026) (US $MN)
Table 23 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Gene Therapy (2016-2026) (US $MN)
Table 24 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cell Therapy (2016-2026) (US $MN)
Table 25 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunotherapy (2016-2026) (US $MN)
Table 26 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Tissue Engineering (2016-2026) (US $MN)
Table 27 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Application (2016-2026) (US $MN)
Table 28 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Dermatology (2016-2026) (US $MN)
Table 29 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 30 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Oncology (2016-2026) (US $MN)
Table 31 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Diabetes (2016-2026) (US $MN)
Table 32 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Orthopedic (2016-2026) (US $MN)
Table 33 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Neurology (2016-2026) (US $MN)
Table 34 North America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Applications (2016-2026) (US $MN)
Table 35 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 36 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 37 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cellular (2016-2026) (US $MN)
Table 38 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Acellular (2016-2026) (US $MN)
Table 39 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Therapy (2016-2026) (US $MN)
Table 40 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Gene Therapy (2016-2026) (US $MN)
Table 41 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cell Therapy (2016-2026) (US $MN)
Table 42 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunotherapy (2016-2026) (US $MN)
Table 43 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Tissue Engineering (2016-2026) (US $MN)
Table 44 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Application (2016-2026) (US $MN)
Table 45 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Dermatology (2016-2026) (US $MN)
Table 46 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 47 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Oncology (2016-2026) (US $MN)
Table 48 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Diabetes (2016-2026) (US $MN)
Table 49 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Orthopedic (2016-2026) (US $MN)
Table 50 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Neurology (2016-2026) (US $MN)
Table 51 Europe Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Applications (2016-2026) (US $MN)
Table 52 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 53 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 54 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cellular (2016-2026) (US $MN)
Table 55 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Acellular (2016-2026) (US $MN)
Table 56 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Therapy (2016-2026) (US $MN)
Table 57 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Gene Therapy (2016-2026) (US $MN)
Table 58 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cell Therapy (2016-2026) (US $MN)
Table 59 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunotherapy (2016-2026) (US $MN)
Table 60 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Tissue Engineering (2016-2026) (US $MN)
Table 61 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Application (2016-2026) (US $MN)
Table 62 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Dermatology (2016-2026) (US $MN)
Table 63 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 64 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Oncology (2016-2026) (US $MN)
Table 65 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Diabetes (2016-2026) (US $MN)
Table 66 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Orthopedic (2016-2026) (US $MN)
Table 67 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Neurology (2016-2026) (US $MN)
Table 68 Asia Pacific Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Applications (2016-2026) (US $MN)
Table 69 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 70 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 71 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cellular (2016-2026) (US $MN)
Table 72 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Acellular (2016-2026) (US $MN)
Table 73 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Therapy (2016-2026) (US $MN)
Table 74 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Gene Therapy (2016-2026) (US $MN)
Table 75 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cell Therapy (2016-2026) (US $MN)
Table 76 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunotherapy (2016-2026) (US $MN)
Table 77 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Tissue Engineering (2016-2026) (US $MN)
Table 78 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Application (2016-2026) (US $MN)
Table 79 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Dermatology (2016-2026) (US $MN)
Table 80 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 81 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Oncology (2016-2026) (US $MN)
Table 82 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Diabetes (2016-2026) (US $MN)
Table 83 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Orthopedic (2016-2026) (US $MN)
Table 84 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Neurology (2016-2026) (US $MN)
Table 85 South America Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Applications (2016-2026) (US $MN)
Table 86 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 87 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 88 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cellular (2016-2026) (US $MN)
Table 89 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Acellular (2016-2026) (US $MN)
Table 90 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Therapy (2016-2026) (US $MN)
Table 91 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Gene Therapy (2016-2026) (US $MN)
Table 92 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cell Therapy (2016-2026) (US $MN)
Table 93 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunotherapy (2016-2026) (US $MN)
Table 94 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Tissue Engineering (2016-2026) (US $MN)
Table 95 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Application (2016-2026) (US $MN)
Table 96 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Dermatology (2016-2026) (US $MN)
Table 97 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Cardiovascular (2016-2026) (US $MN)
Table 98 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Oncology (2016-2026) (US $MN)
Table 99 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Diabetes (2016-2026) (US $MN)
Table 100 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Orthopedic (2016-2026) (US $MN)
Table 101 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Neurology (2016-2026) (US $MN)
Table 102 Middle East & Africa Translational Regenerative Medicines ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Applications (2016-2026) (US $MN)

Companies Mentioned:

Vericel Corporation
Gamida Cell Ltd.
Athersys, Inc.
Orthofix International N.V
Anika Therapeutics
Novartis
Celgene Corporation
Brainstorm Cell Therapeutics Inc.
Nuvasive, Inc.
Medipost

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.